Effect of Omega-3 Fatty Acid Supplementation on the Postprandial Metabolism of Apolipoprotein(a) in Familial Hypercholesterolemia

Qidi Ying1, Mikaël Croyal2,3,4, Dick C Chan1, Valentin Blanchard5, Jing Pang1, Michel Krempf6 and Gerald F Watts1,7

1Medical School, University of Western Australia, Perth, Western Australia, Australia.
2Nantes Université, CNRS, INSERM, l’institut du thorax, F-44000 Nantes, France.
3Nantes Université, CHU Nantes, INSERM, CNRS, SFR Santé, INSERM UMS 016, CNRS UMS 3556, F-44000 Nantes, France.
4CRNH-Ouest Mass Spectrometry Core Facility, F-44000 Nantes, France.
5Department of Medicine, Centre for Heart Lung Innovation, Providence Healthcare Research Institute, St. Paul’s Hospital, University of British Columbia, Vancouver, Canada.
6Clinique Bretêché, Groupe Elsan, Nantes, France
7Lipid Disorders Clinic, Department of Cardiology and Internal Medicine, Royal Perth Hospital, Perth, Western Australia, Australia

**Aim:** Lipoprotein(a) (Lp(a)) is a low-density lipoprotein-like particle containing apolipoprotein(a) (apo(a)) that increases the risk of atherosclerotic cardiovascular disease (ASCVD) in familial hypercholesterolemia (FH). Postprandial redistribution of apo(a) protein from Lp(a) to triglyceride-rich lipoproteins (TRLs) may also increase the atherogenicity of TRL particles. Omega-3 fatty acid (ω3FA) supplementation improves postprandial TRL metabolism in FH subjects. However, its effect on postprandial apo(a) metabolism has yet to be investigated.

**Methods:** We carried out an 8-week open-label, randomized, crossover trial to test the effect of ω3FA supplementation (4 g/day) on postprandial apo(a) responses in FH patients following ingestion of an oral fat load. Postprandial plasma total and TRL-apo(a) concentrations were measured by liquid chromatography with tandem mass spectrometry, and the corresponding areas under the curve (AUCs) (0–10h) were determined using the trapezium rule.

**Results:** Compared with no ω3FA treatment, ω3FA supplementation significantly lowered the concentrations of postprandial TRL-apo(a) at 0.5 (−17.9%), 1 (−18.7%), 2 (−32.6%), and 3 h (−19.2%) (P<0.05 for all). Postprandial TRL-apo(a) AUC was significantly reduced with ω3FA by 14.8% (P<0.05). By contrast, ω3FA had no significant effect on the total AUCs of apo(a), apoC-III, and apoE (P>0.05 for all). The decrease in postprandial TRL-apo(a) AUC was significantly associated with changes in the AUC of triglycerides (r=0.600; P<0.01) and apoB-48 (r=0.616; P<0.01).

**Conclusions:** Supplementation with ω3FA reduces postprandial TRL-apo(a) response to a fat meal in FH patients; this novel metabolic effect of ω3FA may have implications on decreasing the risk of ASCVD in patients with FH, especially in those with elevated plasma triglyceride and Lp(a) concentrations. However, the clinical implications of these metabolic findings require further evaluation in outcome or surrogate endpoint trials.

**Key words:** Atherosclerotic cardiovascular disease, Familial hypercholesterolemia, Fish oil, Lipoprotein(a), Postprandial dyslipidemia

**Introduction**

Familial hypercholesterolemia (FH) is a dominantly inherited disorder commonly due to mutations in the low-density lipoprotein (LDL) receptor that cause markedly elevated plasma LDL-
cholesterol concentrations and increased risk of atherosclerotic cardiovascular disease (ASCVD)\(^1\)-\(^4\). Despite treated with high-intensity statins and/or ezetimibe, a significant proportion of FH patients remains at increased lipoprotein-mediated residual risk of ASCVD\(^3\)-\(^6\). This relates to not achieving LDL-cholesterol targets as well as to abnormalities in the metabolism of triglyceride-rich lipoproteins (TRLs) and lipoprotein(a) (Lp(a))\(^7\),\(^8\).

Abnormal metabolism of TRL may lead to the development of ASCVD in FH owing to prolonged accumulation of TRLs in the circulation, including very-low-density lipoprotein (VLDL)-apolipoprotein (apo) B-100 and apoB-48-containing chylomicrons and their remnants in the circulation\(^7\),\(^8\). TRL remnants are atherogenic, contributing to inflammation, oxidative stress, endothelial dysfunction, and foam cell formation\(^9\). Postprandial redistribution of apo(a) protein from Lp(a) to TRLs particles may also increase the atherogenicity of TRL particles\(^10\),\(^11\).

Elevated Lp(a) enhances atherosclerotic aortic valve disease (CAVD) in FH owing to its atherogenic, thrombogenic, and proinflammatory properties\(^12\)-\(^16\). Recent studies have also reported that Lp(a) is associated with lipid and apolipoprotein profiles and metabolic factors, such as triglycerides, apoB, apoE, and proprotein convertase subtilisin/kexin type 9\(^17\). Lp(a) is a highly polymorphic particle consisting of an LDL-like particle and a protein moiety consisting of apoB-100 covalently bound to apo(a)\(^18\). The metabolism of Lp(a) in humans is poorly understood. Experimental evidence suggests that the apoB-100-apo(a) complex within Lp(a) particles has high affinity for TRL particles\(^10\),\(^11\). A significant proportion of Lp(a) particles can bind non-covalently to TRLs in the hypertriglyceridemic state\(^19\). The Lp(a)-TRL complex may aggravate the pathogenesis of ASCVD in FH. Understanding the metabolism of apo(a) within the TRL fraction in the postprandial state is important to further elucidate the role of Lp(a) in atherosclerosis, as this remains unexplained.

Fish oil is a rich source of long-chain omega-3 fatty acids (\(\omega3\) FAs), primarily eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)\(^20\). Compelling evidence suggests that \(\omega3\) FA supplementation protects against ASCVD through multiple mechanisms, including improvements in hypertriglycerideremia, blood pressure, and inflammation\(^20\)-\(^22\). We have previously reported that \(\omega3\) FA supplementation lowered fasting and postprandial concentrations of triglycerides, VLDL-apoB-100, and apoB-48 in FH patients\(^23\). Whether \(\omega3\) FA supplementation also improves the postprandial response of Lp(a) particle concentration in FH patients remains to be investigated.

In the present study, we investigate the responses of total apo(a) and TRL-apo(a) concentrations to an oral fat load. We hypothesized that \(\omega3\) FA supplementation lowers the postprandial response of plasma TRL-apo(a) in FH patients on statin and/or ezetimibe treatment.

**Methods**

**Subjects and Clinical Protocol**

Full details of the study design and protocol have been previously published\(^23\). Briefly, a total of 20 patients (10 men and 10 women) with FH aged 18–70 years (body mass index [BMI] <40 kg/m\(^2\)) completed the study. FH was defined by the presence of a pathogenic mutation in the LDLR gene (definite FH) and/or a Dutch Lipid Clinic Network criteria score of more than 8 (phenotypic definite FH)\(^5\),\(^6\).

Eligible patients were on statins (or statin plus ezetimibe) at recruitment and throughout the duration of the study. In this 8-week open-label, randomized, crossover trial, all FH patients were randomized into one of the following groups: no \(\omega3\) FA treatment (i.e. standard care only) or an 8-week treatment period of 4 g/day \(\omega3\) FA supplementation (Omacor\(^2\) 46% EPA and 38% DHA in ethyl ester form; Abbott Products Pty Ltd.) with an 8-week washout period between each intervention. The study was approved by the Human Research Ethics Committee of the Royal Perth Hospital and informed written consent was obtained from all subjects.

**Comparison with Non-FH Controls**

For comparison, 10 healthy non-FH subjects (5 men and 5 women, age 60±7 years, BMI 29.8±4.9 kg/m\(^2\), systolic blood pressure 124±13 mmHg, diastolic blood pressure 76±7 mmHg, plasma triglycerides 1.6±0.8 mmol/L, and total cholesterol 5.3±0.7 mmol/L on no drug treatment) were also recruited from the community via newspaper advertisement, in which the fat load test was performed in one occasion only.

**Postprandial Oral Fat Load Test**

Subjects were admitted to the metabolic ward in the morning after a 14-h fast. They were studied in a semi-recumbent position and allowed to drink only water after the test meal. After a baseline fasting blood sample was collected, a liquid-formulated high fat test meal was consumed within 2 min (a total of 4800 kJ, 130 g of fat, 17 g of protein, and 21 g of carbohydrates), following which blood samples were...
Postprandial oral fat loading test were repeated after the 8-week intervention period.

**Biochemical Measurements**

Fasting blood samples were collected at the end of each treatment period. Briefly, fasting whole venous blood samples collected in EDTA were immediately centrifuged at 1500 × g for 15 min at 4°C. Plasma was collected and stored at −80°C. Plasma lipid and glucose concentrations were measured using enzymatic methods (Roche Diagnostics Australia, Castle Hill, NSW, Australia). LDL-cholesterol was estimated using the Friedewald calculation. Fasting insulin was measured using a chemiluminescent immunometric assay (Abbott Diagnostics, North Ryde, NSW, Australia), and insulin resistance was estimated using the homeostasis model assessment (HOMA). Plasma hsCRP was measured using a high-sensitivity polyclonal antibody assay (Abbott Laboratories, Abbott Park, IL, USA). Plasma apoB-48 levels were measured using an enzyme immunoassay kit (Fujirebio, Tokyo, Japan). The TRL fraction was isolated from 3.5 mL of plasma by ultracentrifugation (Optima XL-100K; Beckman Coulter, Australia) at a density of less than 1.006 g/mL (40,000 rpm, 16 h, 4°C). Plasma VLDL-apoB-100 was measured in the TRL fraction using an ELISA kit (Mabtech, Nacka, Sweden). The kit is specific for apoB-100 and does not recognize apoB-48. Total Lp(a) mass concentration was measured using an automated latex enhanced immunoassay (Quanta Lp(a) assay and standards; Abbott Laboratories). The fasting and postprandial apo(a) in the plasma and TRL fraction (density < 1.006 g/mL) were determined as particle number in nmol/L using trypsin proteolysis and subsequent analysis of proteotypic peptides by liquid chromatography with tandem mass spectrometry (LC-MS/MS), as described previously. Non–TRL-apo(a) was calculated as the difference between plasma total apo(a) and TRL-apo(a) concentrations. Fasting and postprandial apoC-III and apoE concentrations (total and apoB-containing lipoprotein [LpB] fractions), as well as apoE phenotyping, were also determined by LC-MS/MS, as previously described. Postprandial metabolism was quantified by calculating the area under the curve (AUC) for plasma total apo(a), TRL-apo(a), and non-TRL-apo(a) (0–10 h) using the trapezium rule.

**Statistical Analyses**

All data were analyzed using the SPSS 26 (SPSS, Chicago, IL, USA) software. Data are reported as mean ± SEM, unless specified otherwise. Skewed variables were log-transformed. The groups were compared using independent t-tests or Fisher’s test. Carryover effects of the crossover design were estimated using general linear modeling (PROC GLM SAS 9.2; SAS Institute). If the carryover effect was not statistically significant, then the data from the two periods (i.e., no ω3FA treatment period vs ω3FA treatment period) was compared using a paired t test to estimate the treatment effect of ω3FA supplementation in our FH patients. Associations were examined using a simple linear regression method. Significance was defined at the 5% level using a two-tailed test.

**Results**

**Baseline Characteristics**

On average, the FH patients were middle aged (53.3 ± 3.0 years), non-obese (BMI 27.0 ± 1.4 kg/m²), and normotensive (systolic blood pressure 124 ± 2.9 mmHg and diastolic blood pressure 69.3 ± 1.9 mmHg). None of the FH patients were current smokers. Seventeen patients were genetically diagnosed with FH (pathogenic mutations in the LDLR gene) and the other 3 had a DLCN score of more than 8 (phenotypic definite FH). Thirteen of the 20 subjects carried the apoE3/E3 phenotype, 4 the apoE3/E4 phenotype, 2 the apoE2/E3 phenotype, and 1 the apoE2/E4 phenotype. Nine patients were on rosvastatin (12.5–40 mg/day), 8 on atorvastatin (40–80 mg/day), and 3 on simvastatin (80 mg/day). Thirteen patients were also on ezetimibe (10 mg/day), 9 on aspirin, 3 on anti-hypertension medication, and 4 reported a history of coronary artery disease (CAD).

**Body Weight, Blood Pressure, and Biochemical Characteristics**

The effect of ω3FA supplementation on body weight, blood pressure, plasma lipid and lipoprotein concentrations, and postprandial triglycerides, VLDL-apoB-100 and apoB-48 total AUCs in 20 FH patients has been previously reported. Briefly, body weight, waist circumference, and BMI did not change significantly during the intervention (P > 0.05 for all). ω3FA supplementation significantly lowered the systolic and diastolic blood pressures, fasting plasma triglycerides, and plasma apoB-100, VLDL-apoB-100, and apoB-48 concentrations (P < 0.05 for all). ω3FA supplementation also lowered plasma apoE concentration, albeit not significantly (P = 0.053). Total cholesterol, LDL-cholesterol, hsCRP, apoC-III, and Lp(a) concentrations were not significantly altered with ω3FA supplementation, nor were the glucose
and insulin concentrations and HOMA score (Table 1). ω-3FA supplementation was also significantly associated with a decrease in postprandial triglyceride and VLDL-apoB-100 total AUCs (−19% and −26%, respectively, \( P < 0.01 \)). The postprandial apoB-48 total AUC (0–10 h) was significantly reduced with ω-3FA supplementation (−30%, \( P < 0.05 \)). The AUCs of apoC-III and apoE (total and LpB fraction) did not change significantly during the intervention (\( P > 0.05 \) for all) (Supplementary Table 1).

### Postprandial Responses of Total and TRL-Apo(a)

Fig. 1 shows the postprandial responses of plasma total apo(a) and TRL-apo(a) to the fat load (0–10 h) before and after 8 weeks of ω-3FA supplementation. In the no ω-3FA treatment period, there was a small but significant increase in the plasma total apo(a) concentration following the first hour of the fat load (\( P < 0.05 \)), which then progressively decreased, returning to the baseline levels at 10 h (Fig. 1A). Following the oral fat load, there was a significant increase in the plasma TRL-apo(a) concentration, which reached a maximum at 2 h postprandially (\( P < 0.05 \)) followed by a return approximately to baseline levels at 10 h (Fig. 1B). When expressed as the percentage of the total apo(a) protein, the proportion of apo(a) in TRL at 0.5 (23.7% ± 11.2%), 1 (23.9% ± 12.6%), 2 (25.8% ± 15.0%), and 3 h (24.5% ± 11.0%) was significantly higher than that at baseline (19.9% ± 6.7%; \( P < 0.05 \) in all). Compared with baseline levels, there was no significant difference in the plasma concentration of apo(a) in the non-TRL fraction following the oral fat load (\( P > 0.05 \), data not shown), except for a significant increase in apo(a) concentration at 1 h (\( P < 0.05 \)) (Supplementary Table 2).

The fasting total apo(a) concentration was significantly associated with the AUC of TRL-apo(a) (\( r = 0.809; \ P < 0.001 \)). The fasting TRL-apo(a) concentration was also significantly associated with the AUC of TRL-apo(a) (\( r = 0.949; \ P < 0.001 \)). The AUCs of total apo(a) or TRL-apo(a) were not associated with the AUCs for plasma triglycerides, VLDL-apoB-100, apoB-48, apoC-III, and apoE (data not shown).

### Comparison of Postprandial Responses of Total and TRL-Apo(a) between FH and Non-FH Subjects

Age, body weight, BMI, and systolic and diastolic blood pressures were not significantly different between the FH patients and non-FH controls (\( P > 0.05 \) for all). Eight of the control subjects carried the apoE3/E3 genotype and two the apoE3/E4 phenotype. The frequency of the apoE phenotype was not significantly different between the groups (\( P > 0.05 \)). While there was also no significant difference in the fasting plasma total apo(a) concentrations between the FH and control groups (\( P > 0.05 \)), FH patients

### Table 1. Effects of ω-3FA supplementation on clinical and biochemical characteristics in 20 FH patients

|                          | No ω-3FA Treatment | ω-3FA | \( P \) value |
|--------------------------|--------------------|-------|--------------|
| Weight (kg)              | 79.1 ± 3.6         | 79.0 ± 3.5 | 0.800       |
| Waist circumference (cm) | 90.5 ± 2.9         | 90.4 ± 3.1 | 0.884       |
| Body mass index (kg/m²)  | 27.0 ± 1.4         | 27.0 ± 1.3 | 0.702       |
| Systolic blood pressure (mmHg) | 124 ± 2.9   | 117 ± 3.4 | 0.009       |
| Diastolic blood pressure (mmHg) | 69.3 ± 1.9 | 65.1 ± 1.9 | 0.006       |
| Total cholesterol (mmol/L) | 4.58 ± 0.27     | 4.20 ± 0.16 | 0.069       |
| LDL-cholesterol (mmol/L)  | 2.81 ± 0.29        | 2.54 ± 0.16 | 0.204       |
| Triglycerides (mmol/L)    | 1.30 ± 0.14        | 1.05 ± 0.09 | 0.011       |
| ApoB (g/L)               | 0.83 ± 0.06        | 0.76 ± 0.03 | 0.038       |
| VLDL-apoB-100 (mg/L)     | 77.2 ± 6.2         | 56.5 ± 4.9 | 0.001       |
| ApoB-48 (mg/L)           | 8.77 ± 1.72        | 5.64 ± 0.81 | 0.026       |
| ApoC-III (mg/L)          | 85.5 ± 7.5         | 81.7 ± 7.6 | 0.627       |
| ApoE (mg/L)              | 66.3 ± 5.1         | 59.4 ± 4.3 | 0.052       |
| Hs-CRP (mg/L)            | 1.90 ± 0.54        | 1.79 ± 0.54 | 0.602       |
| Lipoprotein(a) (g/L)     | 0.44 ± 0.11        | 0.42 ± 0.10 | 0.134       |
| Glucose (mmol/L)         | 5.19 ± 0.10        | 5.32 ± 0.11 | 0.122       |
| Insulin (mU/L)           | 7.79 ± 1.00        | 8.81 ± 0.94 | 0.249       |
| HOMA score               | 1.81 ± 0.24        | 2.09 ± 0.22 | 0.174       |

Data presented as Mean ± SEM; HOMA, homeostatic model assessment; the values of clinical and biochemical characteristics were determined at the end of each 8 week treatment period.
had a higher fasting plasma TRL-apo(a) concentration ($P<0.05$) (Table 2). FH patients also had a higher percentage of apo(a) in the TRL fraction (19.9% ± 6.7% vs. 5.9% ± 2.1%; $P<0.001$) and showed a greater postprandial TRL-apo(a) AUC response to the fat load than the non-FH controls ($P<0.05$). However, there was no significant difference in the postprandial total apo(a) AUC response between the groups ($P>0.05$). The concentration and total AUCs of apoE, but not apoC-III, were significantly higher in FH patients than in the non-FH controls (Supplementary Table 3).

**ω3FA Intervention**

The postprandial responses in the plasma total apo(a) and TRL-apo(a) to the fat load are shown in Table 3. Compared with the no ω3FA treatment period, ω3FA supplementation reduced the rise in total and TRL-apo(a) concentrations in response to the fat load at 0.5 (−17.9%), 1 (−18.7%), 2 (−32.6%),

### Table 2. Plasma apolipoprotein(a) concentration and area under curves in the two groups

| Apolipoprotein(a) | Control ($n=10$) | FH ($n=20$) | $P$ value |
|-------------------|-----------------|-------------|-----------|
| **Total**         |                 |             |           |
| Concentration     | 92.7 ± 112      | 86.4 ± 97.7 | 0.875     |
| AUC               | 973 ± 1152      | 917 ± 1009  | 0.893     |
| **TRL**           |                 |             |           |
| Concentration     | 5.7 ± 8.1       | 14.4 ± 9.7  | 0.022     |
| AUC               | 60.1 ± 94.1     | 182 ± 125   | 0.012     |

Mean ± SD; AUC: area under curve; TRL: triglyceride-rich lipoprotein; FH: familial hypercholesterolemia

*Concentration expressed as nmol/L and AUC as nmol/L •10 h
with the AUCs of VLDL-apoB-100, apoC-III, and apoE with \( \Delta \text{FA} \) supplementation (\( \Delta \text{FA} < 0.05 \) for all, data not shown).

**Discussion**

We demonstrated that FH patients had impaired postprandial TRL-apo(a) response to a fat load and that these abnormalities were partially corrected by \( \Delta \text{FA} \) supplementation. This was reflected in the decrease in the total AUC of TRL-apo(a). We also found that the percentage change in TRL-apo(a) AUC with \( \Delta \text{FA} \) supplementation was significantly associated with the corresponding changes in the AUCs of triglycerides and apoB-48, but not with those of VLDL-apoB-100, apoC-III, and apoE.

**Previous Studies**

Several studies have examined the metabolism of

| Table 3. Effects of \( \Delta \text{FA} \) supplementation on postprandial total apo(a) (A) and TRL-apo(a) (B) concentrations in the FH patients |
|-------------------------------------------------|
| (A) Total apo(a) (nmol/L) | \( \Delta \text{FA} \) | \( \% \) |
|---|---|---|
| No \( \Delta \text{FA} \) Treatment | \( \Delta \text{FA} \) | \( \% \) |
| 0h | 86.4 \( \pm \) 21.8 | 86.6 \( \pm \) 21.6 | 0 | 0.884 |
| 0.5h | 97.8 \( \pm \) 25.4 | 90.7 \( \pm \) 22.2 | -7.3 | 0.229 |
| 1h | 103 \( \pm \) 27.3 | 95.6 \( \pm \) 23.8 | -7.2 | 0.422 |
| 2h | 97.6 \( \pm \) 21.5 | 90.7 \( \pm \) 20.3 | -7.1 | 0.255 |
| 3h | 94.2 \( \pm \) 23.4 | 92.9 \( \pm \) 23.9 | -1.4 | 0.705 |
| 5h | 92.4 \( \pm \) 23.1 | 85.0 \( \pm \) 20.2 | -8.0 | 0.146 |
| 6h | 90.0 \( \pm \) 21.9 | 85.0 \( \pm \) 21.9 | -5.6 | 0.266 |
| 8h | 85.6 \( \pm \) 22.1 | 89.1 \( \pm \) 24.9 | 4.1 | 0.537 |
| 10h | 85.5 \( \pm \) 21.1 | 85.7 \( \pm \) 21.0 | 0.2 | 0.938 |
| AUC | 917 \( \pm \) 226 | 888 \( \pm \) 222 | -3.2 | 0.191 |
| (B) TRL-apo(a) (nmol/L) | \( \Delta \text{FA} \) | \( \% \) |
|---|---|---|
| No \( \Delta \text{FA} \) Treatment | \( \Delta \text{FA} \) | \( \% \) |
| 0h | 14.4 \( \pm \) 2.2 | 14.8 \( \pm \) 2.4 | 2.8 | 0.566 |
| 0.5h | 19.0 \( \pm \) 3.1 | 15.6 \( \pm \) 2.3 | -17.9 | 0.027 |
| 1h | 20.3 \( \pm \) 3.6 | 16.5 \( \pm \) 2.5 | -18.7 | 0.013 |
| 2h | 22.4 \( \pm \) 4.5 | 15.1 \( \pm \) 2.3 | -32.6 | 0.029 |
| 3h | 19.8 \( \pm \) 3.4 | 16.0 \( \pm \) 2.5 | -19.2 | 0.047 |
| 5h | 17.7 \( \pm \) 3.1 | 15.7 \( \pm \) 2.5 | -11.3 | 0.200 |
| 6h | 17.8 \( \pm \) 2.9 | 16.5 \( \pm \) 2.7 | -7.3 | 0.265 |
| 8h | 15.7 \( \pm \) 2.3 | 14.6 \( \pm \) 2.0 | -7.0 | 0.419 |
| 10h | 16.5 \( \pm \) 2.5 | 14.5 \( \pm \) 2.2 | -12.1 | 0.156 |
| AUC | 182 \( \pm \) 29 | 155 \( \pm \) 22 | -14.8 | 0.024 |

Data presented as mean \( \pm \) SEM;
apo(a): apolipoprotein(a); AUC: area-under curve; TRL: triglyceride-rich lipoprotein

* \( P \) values compared with no treatment group using \( t \)-test.

Bold values denote statistically significance at the \( P < 0.05 \).

\( ^{\dagger} \) \( P \) < 0.05 compared with fasting levels at 0hr

and 3 h (−19.2%) (\( P < 0.05 \) in all). There was no significant effect on the fasting total apo(a) and TRL-apo(a) with \( \Delta \text{FA} \) supplementation (\( P > 0.05 \) for both). \( \Delta \text{FA} \) supplementation lowered postprandial plasma total apo(a) AUC (−3.2%), although not significantly (\( P = 0.191 \)). Postprandial TRL-apo(a) AUC (0–10 h) was significantly reduced by 15% with \( \Delta \text{FA} \) supplementation (\( P < 0.05 \)). There was no significant effect on fasting concentration and postprandial AUC for non-TRL-apo(a) with \( \Delta \text{FA} \) supplementation (data not shown; \( P > 0.05 \) for both). \( \Delta \text{FA} \) supplementation had no significant effect on fasting and postprandial apo(a) in the non-TRL fraction (\( P > 0.05 \), Supplementary Table 2).

The percentage change in TRL-apo(a) AUC with \( \Delta \text{FA} \) supplementation was significantly associated with the corresponding percentage changes in the AUCs of triglycerides (Fig. 2A; \( r = 0.600 \); \( P = 0.007 \)) and apoB-48 (Fig. 2B; \( r = 0.616 \); \( P = 0.005 \)), but not with the AUCs of VLDL-apoB-100, apoC-III, and apoE with \( \Delta \text{FA} \) supplementation (\( P > 0.05 \) for all, data not shown).
protocols (time points for blood sampling). Our present data add to previous studies by investigating the postprandial responses for total apo(a) and TRL-apo(a) in subjects with FH. We also examine the effect of high-dose ω-3 FA supplementation (4 g/day) on postprandial total and TRL-apo(a) in response to a fat load in FH patients against a background of cholesterol-lowering treatment (i.e., statin with or without ezetimibe).

TRL-apo(a) metabolism in FH

Fasting State

Experimental evidence suggests that the TRL-apo(a) complex is particularly atherogenic. This relates to an accumulation of lipids in macrophages, delayed chylomicron remnant clearance, and increased arterial uptake of apo(a) via VLDL receptors. Several mechanisms have been proposed for the presence of apo(a) in TRL. It is possible that apo(a) is secreted by the liver as a component of VLDL. Alternatively, the apoB-100-apo(a) complex

apo(a) in non-FH subjects, with conflicting results showing increased, decreased, or no change in Lp(a) concentration following a fat load. We have previously reported that plasma Lp(a) concentrations did not significantly change after oral fat load in statin-treated patients with type 2 diabetes. However, none of these studies specifically examined the metabolism of TRL-apo(a) in the postprandial state. In a study of 20 normolipemic men with a wide range of apo(a), Cohn et al. found that TRL-apo(a), but not total apo(a), increased in the postprandial state following a fat-rich meal. In another study of four healthy individuals with an elevated level of plasma Lp(a), Marcoux et al. also found that there was a rise in TRL-apo(a) in the postprandial state, consistent with another report in patients with CAD. However, owing to the small sample size, the increase did not reach statistical significance. The aforementioned discrepant findings might be explained by the small sample sizes and differences in subject characteristics, types of fat load, and study protocols (time points for blood sampling). Our present data add to previous studies by investigating the postprandial responses for total apo(a) and TRL-apo(a) in subjects with FH. We also examine the effect of high-dose ω-3 FA supplementation (4 g/day) on postprandial total and TRL-apo(a) in response to a fat load in FH patients against a background of cholesterol-lowering treatment (i.e., statin with or without ezetimibe).

TRL-apo(a) metabolism in FH

Fasting State

Experimental evidence suggests that the TRL-apo(a) complex is particularly atherogenic. This relates to an accumulation of lipids in macrophages, delayed chylomicron remnant clearance, and increased arterial uptake of apo(a) via VLDL receptors. Several mechanisms have been proposed for the presence of apo(a) in TRL. It is possible that apo(a) is secreted by the liver as a component of VLDL. Alternatively, the apoB-100-apo(a) complex
within the Lp(a) particle may non-covalently bind to TRLs in the circulation\textsuperscript{11}. It is noteworthy that the existence of non-covalent apo(a)-apoB-100 complexes within the secretory pathway in HepG2 cells has recently been reported\textsuperscript{36}. The distribution of plasma apo(a) in the TRL fraction is affected by different physiological conditions. Approximately 2\%–5\% of plasma apo(a) is found in the TRL fraction in healthy normolipidemic individuals\textsuperscript{19}. By contrast, up to 40\%–70\% of plasma apo(a) can be bound to TRL in patients with hypertriglyceridemia\textsuperscript{19}. In the present study, we found that FH patients had a higher percentage of apo(a) detected in the TRL fraction (~20\%) than non-FH controls. This level is comparable to that observed in an earlier study showing that 17\% of plasma apo(a) was associated with TRLs in patients with coronary heart disease\textsuperscript{29}. However, the precise mechanism for the association of apo(a) to TRLs in the fasted state is poorly understood; whether decreased LDLR activity and/or statin use in FH has a role in it remains to be elucidated.

**Postprandial State**

Consistent with previous studies\textsuperscript{10, 11}, we found that the plasma concentration of TRL-apo(a) increased significantly following fat load. The observation that fasting total and TRL-apo(a) levels were significantly associated with the AUC of TRL-apo(a) suggests that the rise in TRL-apo(a) in response to a fat load depends on the fasting apo(a) concentration. It is possible that TRL-apo(a) are secreted directly by the liver in response to the fat load\textsuperscript{37}. The fed state could also preferentially cause increased secretion of larger TRLs, particularly chylomicron particles (density < 1.006), whereby allowing more apo(a) to bind newly synthesized or secreted TRL particles. These potential mechanisms are supported by our results showing a small but significant increase in the plasma total apo(a) concentration following the first hour of fat load. An alternative explanation for the increase in apo(a) in postprandial TRL involves a simple transfer mechanism of apo(a) from non-TRL to TRL particles\textsuperscript{10}. However, given that there was no significant decrease in the plasma concentration of apo(a) in the non-TRL fraction following fat load, this second explanation appears less likely. Nonetheless, this needs to be confirmed in a study with a larger sample size. Accordingly, we also found that our FH patients had impaired postprandial response for TRL-apo(a) (total AUC) compared with non-FH controls. Whether the higher total AUC of TRL-apo(a) was attributable to increased production and/or impaired catabolism of TRL-apo(a) in the fasting and postprandial conditions requires investigation.

Both apoC-III and apoE play a critical role in TRL metabolism\textsuperscript{38, 39}. We previously showed that the metabolism of Lp(a) is modulated by apoE in the post-absorptive state\textsuperscript{25}. In the present study, we found no association between the AUCs of total apo(a) or TRL-apo(a) and the corresponding AUC for apoC-III or apoE in FH patients. This observation suggests that apoC-III and apoE do not play a significant role in the regulation of Lp(a) metabolism in the postprandial state. Statins can regulate the metabolism of apoC-III and apoE \textsuperscript{40, 41}; however, whether this accounts for the negative postprandial findings in our study remains to be confirmed. The effect of the apoE phenotype, particularly the presence of apoE2, may also influence the metabolism of TRL-apo(a)\textsuperscript{42}. Since the number of FH patients with the E2 phenotype was small in our study (n=3), statistical comparison of the concentration and AUC of TRL-apo(a) between FH patients with and without the apoE2 phenotype was not possible. The impact of APOE genotypes on the metabolism of TRL-apo(a) merits further investigation.

**Mode of Action of \( \omega \)3FA Supplementation**

The precise mechanism(s) of action of \( \omega \)3FA supplementation lowering postprandial AUC of TRL-apo(a) is not clear. There is no evidence demonstrating the direct effect of \( \omega \)3FA on the hepatic secretion and clearance of apo(a). We have previously demonstrated that \( \omega \)-3FA supplementation can improve TRL metabolism by decreasing the secretion of apoB-48 in obese subjects\textsuperscript{43}. As discussed earlier, the mechanisms by which TRL-apo(a) concentrations increased following a fat load may involve increase in the secretion of larger TRLs. Consistently, the observed improvement in postprandial TRL-apo(a) metabolism following the first 2 h of fat load is likely to be a consequence of a decrease in the hepatic and/or intestinal secretion of postprandial TRLs with \( \omega \)3FA supplementation. This is also supported by the observed significant association between the percentage change in TRL-apo(a) AUC with those in the AUCs of triglycerides and apoB-48 following treatment with \( \omega \)3FAs. However, we did not find a correlation between the percentage change in TRL-apo(a) AUC and the corresponding percentage change in the AUCs of VLDL-apoB-100 with \( \omega \)3FA supplementation. Hence, it is possible that the apo(a) (free or with apoB-100 complex) in TRLs may preferentially bind to chylomicron remnants, follow their fate, and thus be removed from the circulation by the remnant receptor pathway. Consistent with
Conclusions

FH is associated with an extremely high risk of ASCVD, not all of which is explained by elevation in LDL-cholesterol\(^6\), \(^8\), \(^{12}\), \(^{47}\). Lp(a) can aggravate the development of ASCVD and CAVD in FH. Our data suggest that a significant portion of apo(a) can be distributed in the TRL fraction both in the fasting and postprandial states, which may increase the atherogenicity of TRL particles; whether this is magnified in patients with elevated Lp(a) remains to be confirmed. Our study provides a novel mechanistic insight into the favorable effect of high-dose \(\omega_3\)FA supplementation on TRL-apo(a) metabolism in FH patients on maximally tolerated statin therapy and ezetimibe. Whether the effect of \(\omega_3\)FA supplementation on TRL-apo(a) metabolism is seen in other high-risk conditions other than FH, such as in chylomicronemia syndrome and diabetes mellitus, needs confirmation. Moreover, the cardiovascular benefit of TRL-apo(a) reduction in the Reduction of Cardiovascular Events with EPA-Intervention Trial also merits further investigation\(^48\). In view of the different effects of DHA and EPA on both TRL and LDL metabolism\(^49\), it may be of interest to examine the role of pure DHA and EPA on postprandial apo(a) metabolism. Future studies should examine the effects of new agents, such as inhibitors of angiopoietin-like protein 3 and antisense oligonucleotides against apo(a), in addition to statin therapy on postprandial TRL-apo(a) metabolism\(^50\).

Study Limitations

Our study has several limitations. The sample size was relatively small; hence, we cannot not exclude the possibility that our results showing a significant difference in fasting plasma TRL-apo(a), but not in total apo(a) concentrations, between the FH and control groups might be caused by a type II statistical error. Nevertheless, our findings were consistent with another report in patients with CAD\(^29\). In addition, we might have been unable to detect a significant change in the postprandial total and non-TRL-apo(a) AUCs. In the present study, we found that the fasting total apo(a) concentration was significantly associated with the AUC of TRL-apo(a). Given that low apo(a) isoform size is associated with high plasma Lp(a) level and high risk for ASCVD\(^44\), variations in apo(a) isoform size may affect the non-covalent binding of apo(a) to TRLs. Thus, determination of apo(a) isoform size may help elucidate its impact on the postprandial metabolism of TRL-apo(a). The composition of the fat meal in the current study may confound the effect of \(\omega_3\)FA supplementation on postprandial TRL-apo(a)\(^45\). Hence, our results might have been different if we employed a test meal with a different composition (e.g., low-fat or mixed meal). We did not specifically study FH patients with elevated plasma concentrations of Lp(a). In a subgroup analysis of six FH patients with elevated Lp(a) (>0.5 g/L), we found that \(\omega_3\)FA supplementation reduced the AUC of TRL-apo(a) (337±41 vs. 271±31 nmol/L; \(P<0.05\)). Hence, we consider that our findings could also generally be applied to subjects with elevated Lp(a) concentrations, but this needs to be confirmed in a larger population. We did not measure apo(a) concentration specifically in the VLDL and chylomicron fractions, which might have helped clarify the mechanism of action of \(\omega_3\)FAs on apo(a) metabolism in the postprandial state. Further investigations should examine the relationship between apo(a) isoform and the postprandial metabolism of TRL-apo(a) and the corresponding effects of \(\omega_3\)FA supplementation\(^46\).

Acknowledgements

The authors would like to thank the patients involved in the study. QY is supported by an Australian Government Research Training Program (RTP) Scholarship. JP is supported by National Health and Medical Research Council (NHMRC) Investigator Grant.

Contributors

DCC, JP and GFW designed the study. DC, JP and GFW conducted the study. QY, MC, DCC, VB, JP and MK analysed the data. QY, DCC and GFW drafted the manuscript. All authors reviewed and approved the manuscript.

Funding

The study was supported by a National Health and Medical Research Council project grant and Royal Perth Hospital Medical Research Foundation
research grant.

**Competing Interests**

GFW has received honoraria for advisory boards and research grants from Amgen, Arrowhead, Esperion, AstraZeneca, Kowa, Novartis, Pfizer, Sanofi and Regeneron.

**Data Availability**

The protocol/data that support the findings of this study are available from the corresponding author on reasonable request.

**Clinical Trial Registration**

https://www.clinicaltrials.com/ NCT01577056

**References**

1) Borén J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, Daemen MJ, Demer LL, Hegele RA, Nicholls SJ, Nordestgaard BG, Watts GF, Bruckert E, Fazio S, Ference GA, Graham I, Horton JD, Landmesser U, Laufs U, Masana L, Pasterkamp G, Raal FJ, Ray KK, Schunkert H, Taskinen MR, van de Sluis B, Wiklund O, Tokgozoglu L, Catapano AL, Ginsberg HN: Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J, 2020; 41: 2313-2330

2) Hu P, Dharmayat KI, Stevens CAT, Sharabiani MTA, Jones RS, Watts GF, Genest J, Ray KK, Vallejo-Vaz AJ: Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: A systematic review and meta-analysis. Circulation, 2020; 141: 1742-1759

3) Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham I, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group: 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J, 2020; 41: 111-188

4) Grundy SM, Stone NJ, Bailey AL, Beam C, Bircher KK, Blumenthal RS, Braun LT, de Ferranti S, Failla-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeoah J: 2018 AHA/ACC/AACVPR/ABC/ACPM/ADA/AGS/Apha/ASPc/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelnes. Circulation, 2019; 139: e1082-e1143

5) Watts GF, Sullivan DR, Hare DL, Kostner KM, Horton AE, Bell DA, Brett T, Trent RJ, Poplawski NK, Martin AC, Srinivasan S, Justo RN, Chow CK, Pang J: FH Australasia Network Consensus Working Group: Integrated guidance for enhancing the care of familial hypercholesterolaemia in Australia. Heart Lung Circ, 2021; 30: 324-349

6) Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna M, Borén J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybjaerg-Hansen A; European Atherosclerosis Society Consensus Panel: Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J, 2013; 34: 3478-3490

7) Chemello K, García-Nafria J, Gallo A, Martín C, Lambert G, Blom D: Lipoprotein metabolism in familial hypercholesterolemia. J Lipid Res, 2021; 62: 100062

8) Chan DC, Watts GF: Postprandial lipoprotein metabolism in familial hypercholesterolemia: thinking outside the box. Metabolism, 2012; 61: 3-11

9) Ginsberg HN, Packard CJ, Chapman MJ, Borén J, Aguilar-Salinas CA, Averna M, Ference BA, Gaudet D, Hegele RA, Kersten S, Lewis GF, Lichtenstein AH, Moulin P, Nordestgaard BG, Remaley AT, Staels B, Stroes ESG, Taskinen MR, Tokgozoglu LS, Tybjaerg-Hansen A, Stock JK, Catapano A: Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society. Eur Heart J, 2021; 42: 4791-4806

10) Cohn JS, Lam CW, Sullivan DR, Hensley WJ: Plasma lipoprotein distribution of apolipoprotein(a) in the fed and fasted states. Atherosclerosis, 1991; 90: 59-66

11) Marcoux C, Lussier-Cacan S, Davignon J, Cohn JS: Association of Lp(a) rather than integrally-bound apo(a) with triglyceride-rich lipoproteins of human subjects. Biochim Biophys Acta, 1997; 1346: 261-274

12) Alonso R, Andres E, Mata N, Fuentes-Jiménez F, Badimon L, López-Miranda J, Padró T, Muñiz O, Díaz-Díaz JL, Mauri M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ferré BA, Graham I, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group: 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J, 2020; 41: 111-188

13) Cegla J, Neely RDG, France M, Ferns G, Byrne CD, Halcox J, Datta D, Capps N, Shoulders C, Qureshi N, Rees A, Main L, Crumb R, Viljoes A, Payne J, Soran H; HEART UK Medical, Scientific and Research Committee: HEART UK consensus statement on lipoprotein(a): a call to action. Atherosclerosis, 2019; 29: 62-70
14) Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, Lloyd-Jones DM, Marcovina SM, Yeang C, Koschinsky ML; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; and Council on Peripheral Vascular Disease: Lipoprotein(a): A genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: A scientific statement From the American Heart Association. Arterioscler Thromb Vasc Biol, 2022; 42: e48-e60

15) Naito R, Daida H, Masuda D, Harada-Shiba M, Arai H, Bujo H, Ishibashi S, Koga N, Oikawa S, Yamashita S and Group FS: Relation of Serum Lipoprotein(a) Levels to Lipoprotein and Apolipoprotein Profiles and Atherosclerotic Diseases in Japanese Patients with Heterozygous Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study. J Atheroscler Thromb, 2022; 29: 1188-1200

16) Yanaka K, Akahori H, Imanaka T, Miki K, Yoshihara N, Kimura T, Tanaka T, Asakura M and Ishihara M: Relationship Between Lipoprotein(a) and Angiographic Severity of Femoropopliteal Lesions. J Atheroscler Thromb, 2021; 28: 555-561

17) Hamamura H, Adachi H, Enomoto M, Fukami A, Nakamura S, Nohara Y, Morikawa N, Sakaue A, Toyomasu K, Yamamoto M and Fukumoto Y: Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population. J Atheroscler Thromb, 2021; 28: 329-337

18) Schmidt K, Nouren A, Kronenberg F, Utermann G: Structure, function, and genetics of lipoprotein (a). J Lipid Res, 2016; 57: 1339-1359

19) Gaubatz JW, Hoogeveen RC, Hoffman AS, Ghazzaly KG, Pownall HJ, Guevara J, Jr., Koschinsky ML, Morissett JD: Isolation, quantitation, and characterization of a stable complex formed by Lp[a] binding to triglyceride-rich lipoproteins. J Lipid Res, 2001; 42: 2058-2068

20) Nestel PJ: Fish oil and cardiovascular disease: lipids and arterial function. Am J Clin Nutr, 2000; 71: 2285-2315

21) Goldenberg RM, Cheng AY, Gilbert JD, Lonn EM, Pedersen SD, Verma S: The role of icosapent ethyl in cardiovascular risk reduction. Curr Opin Cardiol, 2021; 36: 661-671

22) Weinberg RL, Brook RD, Rubenfire M, Eagle KA: Cardiovascular impact of nutritional supplementation with omega-3 fatty acids: JACC Focus Seminar. J Am Coll Cardiol, 2021; 77: 593-608

23) Chan DC, Pang J, Barrett PH, Sullivan DR, Burnett JR, van Boekhove RM, Watts GF: omega-3 fatty acid ethyl esters diminish postprandial lipemia in familial hypercholesterolemia. J Clin Endocrinol Metab, 2016; 101: 3732-3739

24) Blanchard V, Garçon D, Jaunet C, Chemello K, Billon-Crossouard S, Agueuse A, Garfa A, Fanchon G, Torres A, Le May C, Pichelin M, Bigot-Corbel E, Lambert G, Cariou B, Hadjadj S, Krempf M, Bach-Ngouhou K, Croyal M: A high-throughput mass spectrometry-based assay for large-scale profiling of circulating human apolipoproteins. J Lipid Res, 2020; 61: 1128-1139

25) Croyal M, Blanchard V, Ouquerram K, Chétrieux M, Cabioch L, Moyon T, Billon-Crossouard S, Agueuse A, Bernardeau K, Le May C, Flet L, Lambert G, Hadjadj S, Cariou B, Krempf M, Nobécourt-Dupuy E: VLDL (very-low-density lipoprotein)-apo E (apolipoprotein E) may influence Lp(a) (lipoprotein [a]) synthesis or assembly. Arterioscler Thromb Vasc Biol, 2020; 40: 819-829

26) Emancipator K: Low bias in assayed values of lipoprotein antigens—lipoprotein(a) and apolipoproteins A-I and B—in midday postprandial blood specimens compared with morning fasting specimens. Clin Chem, 1992; 38: 431-433

27) Ishikawa T, Yamashita T, Mochizuki K, Suzuki K, Hashizume N, Nakamura H: Changes in the concentration and distribution of lipoprotein (a) in plasma after fat intake. J Atheroscler Thromb, 1995; 2 Suppl 1: S17-21

28) Souza DR, Maranhão RC, Varella-Garcia M, Vilafanh D, Santos AB, Pileggi F, da Luz PL: Postprandial levels of lipoprotein(a) in subjects with or without coronary artery disease. Int J Cardiol, 1996; 53: 94-96

29) Hoppichler F, Kraft HG, Sandholzer C, Lechleitner M, Patsch JR, Utermann G: Lipoprotein(a) is increased in triglyceride-rich lipoproteins in men with coronary heart disease, but does not change acutely following oral fat ingestion. Atherosclerosis, 1996; 122: 127-134

30) Pirro M, Lupattelli G, Siepi D, Palumbo B, Roscini AR, Marchesi S, Schillaci G, Mannarino E: Postprandial lipemia and associated metabolic disturbances in healthy and hyperlipemic postmenopausal women. Metabolism, 2001; 50: 330-334

31) Igarashi M, Hirata A, Yamauchi T, Yamaguchi H, Tsuchiya H, Ohnuma H, Jimbu Y, Okuyama Y, Shirata R, Otsu N, Fukuyama H, Takahashi S, Tominaog M, Kato T: Clinical utility and approach to estimate postprandial hypertriglyceremia by a newly designed oral fat-loading test. J Atheroscler Thromb, 2003; 10: 314-320

32) Ooi EM, Watts GF, Chan DC, Pang J, Tenneti VS, Hamilton SJ, McCormick SP, Marcovina SM, Barrett PH: Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol, 2015; 35: 2686-2693

33) Bersot TP, Innerarity TL, Pitas RE, Rall SC, Jr., Weisgraber KH, Mahley RW: Fat feeding in humans induces lipoproteins of density less than 1.006 that are enriched in apolipoprotein [a] and that cause lipid accumulation in macrophages. J Clin Invest, 1986; 77: 622-630

34) Devlin CM, Lee SJ, Kuriakose G, Spencer C, Becker L, Grosskopf I, Ko C, Huang LS, Koschinsky ML, Cooper AD, Tabas I: An apolipoprotein(a) peptide delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo. Arterioscler Thromb Vasc Biol, 2005; 25: 1704-1710

35) Edelstein C, Davidson NO, Scanu AM: Oleate stimulates the formation of triglyceride-rich particles containing apoB100-apo(a) in long-term primary cultures of human hepatocytes. Chem Phys Lipids, 1994; 67-68: 135-143
36) Youssef A, Clark JR, Marcovina SM, Boffa MB, Koschinsky ML: Apo(a) and apoB interact noncovalently within hepatocytes: Implications for regulation of Lp(a) levels by modulation of apoB secretion. Arterioscler Thromb Vasc Biol, 2022; 42: 289-304

37) Rainwater DL, Lanford RE: Production of lipoprotein(a) by primary baboon hepatocytes. Biochim Biophys Acta, 1989; 1003: 30-35

38) D’Erasmo L, Di Costanzo A, Gallo A, Bruckert E, Arca M: ApoCIII: A multifaceted protein in cardiometabolic disease. Metabolism, 2020; 113: 154395

39) Marais AD: Apolipoprotein E and atherosclerosis. Curr Atheroscler Rep, 2021; 23: 34

40) Chan DC, Nguyen MN, Watts GF, Ooi EM, Barrett PH: Effects of atorvastatin and n-3 fatty acid supplementation on VLDL apolipoprotein C-III kinetics in men with abdominal obesity. Am J Clin Nutr, 2010; 91: 900-906

41) Ooi EM, Ng TW, Watts GF, Chan DC, Barrett PH: Effect of fenofibrate and atorvastatin on VLDL apoE metabolism in men with the metabolic syndrome. J Lipid Res, 2012; 53: 2443-2449

42) Moriarty PM, Varvel SA, Gordts PL, McConnell JP, Tsimikas S: Lipoprotein(a) mass levels increase significantly according to APOE genotype: An analysis of 431 239 patients. Arterioscler Thromb Vasc Biol, 2017; 37: 580-588

43) Wong AT, Chan DC, Barrett PH, Adams LA, Watts GF: Effect of ω-3 fatty acid ethyl esters on apolipoprotein B-48 kinetics in obese subjects on a weight-loss diet: a new tracer kinetic study in the postprandial state. J Clin Endocrinol Metab, 2014; 99: E1427-1435

44) Erqou S, Thompson A, Di Angelantonio E, Saleheen D, Kaptoge S, Marcovina S, Danesh J: Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol, 2010; 55: 2160-2167

45) Tholstrup T, Samman S: Postprandial lipoprotein(a) is affected differently by specific individual dietary fatty acids in healthy young men. J Nutr, 2004; 134: 2550-2555

46) Pfaffinger D, Schuelke J, Kim C, Fless GM, Scanu AM: Relationship between apo[a] isoforms and Lp[a] density in subjects with different apo[a] phenotype: a study before and after a fatty meal. J Lipid Res, 1991; 32: 679-683

47) Chan DC, Pang J, Hooper AJ, Burnett JR, Bell DA, Bates TR, van Bockxmeer FM, Watts GF: Elevated lipoprotein(a), hypertension and renal insufficiency as predictors of coronary artery disease in patients with genetically confirmed heterozygous familial hypercholesterolemia. Int J Cardiol, 2015; 201: 633-638

48) Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators: Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med, 2019; 380: 11-22

49) Moriarty PM, Varvel SA, Gordanis PL, McConnell JP, Tsimikas S: Lipoprotein(a) mass levels increase significantly according to APOE genotype: An analysis of 431 239 patients. Arterioscler Thromb Vasc Biol, 2017; 37: 580-588

50) Tsimikas S, Moriarty PM, Stroes ES: Emerging RNA therapeutics to lower blood levels of Lp(a): JACC Focus Seminar 2/4. J Am Coll Cardiol, 2021; 77: 1576-1589
## Supplementary Table 1. Effects of ω-3FA supplementation on postprandial area under curves (AUCs) for postprandial triglycerides, very-low-density lipoprotein (VLDL), apolipoproteinB-48 (apoB-48), apolipoprotein C-III (apoC-III) and apolipoprotein E (apoE) responses to the fat load

|                     | No ω-3FA Treatment | ω-3FA |
|---------------------|--------------------|-------|
| Triglycerides (mmol/L•10 h) | 27.8 ± 4.7         | 22.3 ± 3.3** |
| VLDL-apoB-100 (mg/L•10 h) | 964 ± 79           | 702 ± 53*** |
| ApoB-48 (mg/L•10 h) | 190 ± 38           | 137 ± 21*   |
| ApoC-III (mg/L•10 h) |                   |       |
| Total               | 800 ± 82.8         | 730 ± 79.3 |
| LpB fraction        | 472 ± 41           | 452 ± 53   |
| ApoE (mg/L•10 h)    |                   |       |
| Total               | 704 ± 78           | 611 ± 45   |
| LpB fraction        | 380 ± 44           | 345 ± 28   |

Data presented as mean ± SEM; LpB: apoB-containing lipoprotein
*: P<0.05, **: P<0.01, ***: P<0.001 compared with no ω-3FA treatment group using t-test.

## Supplementary Table 2. Effects of ω-3FA supplementation on postprandial apo(a) concentration in non-TRL fraction in the FH patients

|                     | Non-TRL apo(a) (nmol/L) | P value* |
|---------------------|-------------------------|----------|
|                    | No ω-3FA Treatment      | ω-3FA    | %     |
| 0h                  | 76.1 ± 21.0             | 76.0 ± 20.6 | -0.1  | 0.958 |
| 0.5h                | 83.6 ± 24.0             | 79.6 ± 21.2 | -4.8  | 0.505 |
| 1h                  | 88.2 ± 26.0†            | 83.7 ± 23.0 | -5.1  | 0.648 |
| 2h                  | 80.0 ± 18.8             | 80.0 ± 18.9 | -0.0  | 0.991 |
| 3h                  | 79.1 ± 21.5             | 81.4 ± 22.7 | +2.9  | 0.582 |
| 5h                  | 79.2 ± 21.2             | 73.4 ± 19.0 | -7.3  | 0.238 |
| 6h                  | 76.6 ± 20.1             | 72.6 ± 20.9 | -5.2  | 0.415 |
| 8h                  | 74.0 ± 21.5             | 78.9 ± 24.9 | +6.6  | 0.450 |
| 10h                 | 73.1 ± 20.0             | 75.4 ± 20.5 | +3.1  | 0.591 |
| AUC                 | 781 ± 210              | 776 ± 213 | -0.6  | 0.842 |

Data presented as mean ± SEM; apo(a): apolipoprotein(a); AUC: area-under curve; TRL: triglyceride-rich lipoprotein
Non-TRL apo(a) was calculated by subtracting TRL-apo(a) from total apo(a) concentration
*P values compared with no treatment group using t-test.
\(^\dagger\) P values denote statistically significance at the P<0.05
\(^\ddagger\) P<0.05 compared with fasting levels at 0hr

## Supplementary Table 3. Plasma apolipoprotein C-III and apolipoprotein E concentration and area under curves in the two groups

|                     | Control (n=10) | FH (n=20) | P value |
|---------------------|---------------|-----------|---------|
| Apolipoprotein C-III*|               |           |         |
| Total               | 74.1 ± 33.5   | 85.5 ± 33.7 | 0.387   |
| AUC                 | 673 ± 300     | 800 ± 370 | 0.356   |
| Apolipoprotein E*   |               |           |         |
| Total               | 35.1 ± 16.1   | 66.3 ± 22.6 | 0.001   |
| AUC                 | 322 ± 140     | 704 ± 350 | 0.003   |

Mean ± SD; AUC: area under curve; FH: familial hypercholesterolemia
*Concentration expressed as mg/L and AUC as mg/L •10 h